FIGURE 2.

FZHFZY inhibits proliferation and improves epidermal differentiation of interleukin (IL)-17A/IL-22/interferon (IFN)-γ/tumour necrosis factor (TNF)-α–stimulated HaCaT cells. (A) HaCaT cells were treated with IL-17A (10 ng/ml), IL-22 (10 ng/ml), IFN-γ (10 ng/ml) and TNF-α (25 ng/ml) for 24 h, then various concentrations of FZHFZY from 0.625 to 10 mg/ml were added to the wells, followed by another 24-h incubation, and the effects of FZHFZY on cell viability was measured via MTT assay. (B) IL-17A/IL-22/IFN-γ/TNF-α–stimulated HaCaT cells were treated with 1.25 or 2.5 mg/ml FZHFZY for 24 h. Total RNA was isolated from HaCaT cells, and RT-PCR was used to investigate the mRNA levels of various molecules of epidermal differentiation.